

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Shamprasad Varija Raghu

Potential competing interests: No potential competing interests to declare.

The work is interesting. In Figure 2, Iso treatment significantly decreased A β 40 peptide levels compared to untreated cells. Similar observations are shown for A β 42 in Figure 2B. However, the authors claim it is not significant. Any justifications for this conclusion?